In this video Dr. Ashley Frazee explains a recent FDA proposal that would remove semaglutide, tirzepatide, and liraglutide (GLP‑1 drugs) from the list of compounds that large, FDA‑registered 503 bulk‑compounding facilities may produce. She clarifies that while the rule would stop mass‑production by these federally regulated facilities, smaller state‑regulated 503 pharmacies that compound for individual prescriptions could still dispense the drugs under stricter documentation requirements. Dr. Frazee outlines the two tiers of compounding pharmacies—large cGMP‑compliant bulk facilities versus smaller, state‑board‑regulated individual compounding pharmacies—and highlights the apparent contradiction in the FDA’s safety rationale, which removes the drugs from the higher‑standard facilities while pushing patients toward either expensive brand‑name products or lower‑oversight compounding. She notes the pharmaceutical industry’s prior opposition to compounded GLP‑1s, followed by Eli Lilly’s launch of LillyDirect, which now sells tirzepatide in vials directly to patients, suggesting a conflict of interest. The speaker warns that the new restrictions could create additional barriers for patients, requiring physicians to provide detailed clinical justification, and may spur a black‑market for compounded peptides. Finally, she reminds viewers that the rule change must undergo the Administrative Procedure Act’s public comment period, encouraging public participation, and emphasizes her intent to inform patients rather than incite anger.
Chapters
On April 30th, the FDA made a move that's going to affect millions of people who are currently on compounded GLP-1s like semaglutide and tirzepatide, the weight loss and diabetes drugs that have really changed a lot of lives over the past few years. Well, they made a proposal to get 503 pharmacies to stop being allowed to mass-produce these drugs, and most people who have heard about this seem confused because the headlines aren't telling the whole story. They're really just scaring people or clickbaiting you. So let me tell you what happened and why it matters. I'm going to start with an analogy because the pharmaceutical industry is designed to be confusing. But let's just say that we did this with hot dogs. So imagine somebody came up with a life-changing nutritional hot dog that costs $1,000 a month. Most people can't afford that. But if they have food insurance for things like this, the food insurance might pay $200 to $900 for you. If and only if you have a hot dog deficiency. So great, now you spend anywhere from $100 to $800 on the hot dog, but if you qualify. But then a shortage hits. The $1,000 hot dog is literally unavailable. So the FDA steps in and says, okay, well now regular restaurants can make a version of this hot dog. It's not the brand name hot dog, but it's the same recipe and the ingredients meet our standards. And now people who desperately need it can actually get it. So So that's what happened with the GLP-1 drugs like Ozempic and Mounjaro or semaglutide and tirzepatide. For 2 years, the branded drugs were on a shortage. So compounding pharmacies were allowed to mix them up and sell them to you and I. And that worked out well for a lot of people. People got on GLPs at a fraction of the cost and many lives genuinely changed. We also got to see the massive benefit that these things have on a lot of people. But now the FDA says the shortage is over, the $1,000 version of the hot dogs are in stock. And so the neighborhood chefs and all the businesses who jumped on board to distribute the more affordable version of the hot dogs can kick rocks. But in all seriousness, there's a bit of confusion here on what's actually going on, because even though pharmacies aren't allowed to make GLP-1 drugs in bulk anymore, not all compounding pharmacies would be banned from dispensing them to people. So there are 2 types of compounding pharmacies. There are large 503 facilities that are FDA registered. They follow something called CGMP, or Current Good Manufacturing Practices, and this is a federal manufacturing standard. These are the pharmacies that have been bulk compounding semaglutide and tirzepatide during the shortage, which powered a lot of telehealth companies like Hims and other weight loss platforms. Then there are the 503 pharmacies. Well, these are generally smaller compounding pharmacies that fill prescriptions for individuals based on a prescriber's instructions. They are regulated by state boards, not the FDA's federal CGMP standards, meaning they actually operate under a lower regulatory tier. So the FDA just proposed removing semaglutide, tirzepatide, and liraglutide, all GLP-1 drugs, from the 503 bulks list, the larger facility. So now the large federally regulated cGMP compliant manufacturers can no longer mass produce these compounds. And here's a contradiction that I find interesting, and let me know if you do too. The FDA's stated reason for doing this is patient safety and returning to gold standard manufacturing, but they just removed the drug from the facilities that are meeting the higher federal standards, and this will push patients either brand-name drugs, which I think they're hoping for, that they can afford, or smaller 503 pharmacies operating under lower oversight, or nothing. I have nothing against 503 pharmacies, by the way. I'm just saying that if this were truly about safety, that's a strange way to achieve it. The FDA's legal justification is that there is no longer a clinical need for compounded versions of these drugs because the branded drugs are now available. But available doesn't always translate to affordable and easy to acquire. If a drug is on a shelf for $1,000 a month, or even if they lower the price to $400, which was a smart move, Eli Lilly, it still doesn't make it that easy or more accessible. So that's one thing that feels so off to so many people right now. There's also another contradiction that I felt like needed discussing. For 2 years, pharmaceutical companies were a little angry about the compoundable drugs being sold in vials directly to patients. And they claimed that self-injection from a vial was too complicated, too risky, and not appropriate for the general public. But then Eli Lilly launched LillyDirect, selling Zepbound and tirzepatide directly to people in vials. And see, the moment they figured out how to own the distribution channel themselves, now the FDA is moving to shut down the independent versions. Now, 503 pharmacies can still compound the drugs. So people are saying it's fine, just go through a 503 pharmacy. But the reality is that 503 pharmacies cannot make essentially copies of a commercially available drug. The FDA is still tightening that definition, but simply adding B12 to semaglutide or tirzepatide as meaningfully different. To access a compounded version through a 503 pharmacy, patients increasingly need a physician or prescriber to document specific clinical reason why the brand name won't work. Maybe an allergy to an inactive ingredient or a specific dosing need or something very individual. And it's not impossible to do that, but it turns what was a relatively accessible treatment back into a medical obstacle. And not every doctor knows how to navigate that or will take the time to do it. And if I'm being honest, I also don't want to be pigeonholed into lying for my patients. So now I'm just gonna make a prediction. I don't know if this will happen or not, but given that the FDA is also moving several peptides that aren't branded off of the do not compound list in an attempt to get people to stop buying black market peptides, well, I kind of think that this move is going to create more of a black market for the GLP peptides. Because when you take a treatment that really works, that genuinely changes people's health and their quality of life, and you put it behind a bunch of red tape and obstacles, for lack of a better term, people tend to get creative. Now I have to mention this before I stop recording. When the FDA wants to change a rule or a policy, they often can't just flip a switch. They have to go through a formal process under the Administrative Procedure Act. And that process includes a public comment period. And it means, here's what we're planning to do. Before we finalize it, we're giving the public a chance to weigh in. And mostly pharmacies and companies are the ones who will submit comments here, but anybody is allowed to. Just saying. Now, I didn't make this video to make you angry. I made it because when something happens in the system that directly affects the people that I work for, meaning my patients, well, the most useful thing that I can do is explain it clearly. You deserve to understand what's going on because it might affect you or someone you love. I'm Dr. Ashley Frazee. I am a physician and I care about my patients. If you like this video, please hit like for me, subscribe to my channel. Let me know if these kinds of videos are useful for you and I'll keep doing them. I hope you have the best day.
